Imaging agents for the chemokine receptor 4 (CXCR4)

被引:71
|
作者
Kuil, Joeri [1 ,2 ]
Buckle, Tessa [1 ]
van Leeuwen, Fijs W. B. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; BREAST-CANCER METASTASIS; SMALL-MOLECULE INHIBITOR; ANTI-HIV ACTIVITY; ANTAGONIST CTCE-9908; RHEUMATOID-ARTHRITIS; SELECTIVE-INHIBITION; HEMATOPOIETIC STEM; ENTRY INHIBITORS; AGONIST PEPDUCIN;
D O I
10.1039/c2cs35085h
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The interaction between the chemokine receptor 4 (CXCR4) and stromal cell-derived factor-1 (SDF-1, also known as CXCL12) is a natural regulatory process in the human body. However, CXCR4 over-expression is also found in diseases such as cancer, where it plays a role in, among others, the metastatic spread. For this reason it is an interesting biomarker for the field of diagnostic oncology, and therefore, it is gaining increasing interest for applications in molecular imaging. Especially "small-molecule" imaging agents based on T140, FC131 and AMD3100 have been extensively studied. SDF-1, antibodies, pepducins and bioluminescence have also been used to visualize CXCR4. In this critical review reported CXCR4 targeting imaging agents are described based on their affinity, specificity and biodistribution. The level wherein CXCR4 is up-regulated in cancer patients and its relation to the different cell lines and animal models used to evaluate the efficacy of the imaging agents is also discussed (221 references).
引用
收藏
页码:5239 / 5261
页数:23
相关论文
共 50 条
  • [31] Expression and potential role of chemokine receptor CXCR4 in human bladder carcinoma cell lines with different metastatic ability
    Wang, Haifeng
    Yang, Delin
    Wang, Kai
    Wang, Jiansong
    MOLECULAR MEDICINE REPORTS, 2011, 4 (03) : 525 - 528
  • [32] Inhibition of Chemokine Receptor Expression on Uveal Melanomas by CXCR4 siRNA and Its Effect on Uveal Melanoma Liver Metastases
    Li, Haochuan
    Yang, Wanhua
    Chen, Peter W.
    Alizadeh, Hassan
    Niederkorn, Jerry Y.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2009, 50 (12) : 5522 - 5528
  • [33] Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
    Wu, Beili
    Chien, Ellen Y. T.
    Mol, Clifford D.
    Fenalti, Gustavo
    Liu, Wei
    Katritch, Vsevolod
    Abagyan, Ruben
    Brooun, Alexei
    Wells, Peter
    Bi, F. Christopher
    Hamel, Damon J.
    Kuhn, Peter
    Handel, Tracy M.
    Cherezov, Vadim
    Stevens, Raymond C.
    SCIENCE, 2010, 330 (6007) : 1066 - 1071
  • [34] Endothelial Cell Insulin Signaling Regulates CXCR4 (C-X-C Motif Chemokine Receptor 4) and Limits Leukocyte Adhesion to Endothelium
    Rathjen, Thomas
    Kunkemoeller, Britta
    Cederquist, Carly T.
    Wang, Xuanchun
    Lockhart, Sam M.
    Patti, James C.
    Willenbrock, Hanni
    Olsen, Grith Skytte
    Povlsen, Gro Klitgaard
    Beck, Hans Christian
    Rasmussen, Lars Melholt
    Li, Qian
    Park, Kyoungmin
    King, George L.
    Rask-Madsen, Christian
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42 (07) : E217 - E227
  • [35] Urokinase receptor and CXCR4 are regulated by common microRNAs in leukaemia cells
    Alfano, Daniela
    Gorrasi, Anna
    Li Santi, Anna
    Ricci, Patrizia
    Montuori, Nunzia
    Selleri, Carmine
    Ragno, Pia
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2015, 19 (09) : 2262 - 2272
  • [36] Selective synthesis of an elusive C-functional bis-cyclam and study of its inhibition of the CXCR4 chemokine receptor
    Le Roy, Marie M.
    Claes, Sandra
    Saffon-Merceron, Nathalie
    Schols, Dominique
    Troadec, Thibault
    Tripier, Raphael
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2024, 22 (15) : 3059 - 3067
  • [37] Small Molecule Inhibitors of CXCR4
    Debnath, Bikash
    Xu, Shili
    Grande, Fedora
    Garofalo, Antonio
    Neamati, Nouri
    THERANOSTICS, 2013, 3 (01): : 47 - 75
  • [38] The CXCR4/SDF-1 Chemokine Axis: A Potential Therapeutic Target for Bone Metastases?
    Hirbe, A. C.
    Morgan, E. A.
    Weilbaecher, K. N.
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (11) : 1284 - 1290
  • [39] Targeting CXCR4 in AML and ALL
    Cancilla, Daniel
    Rettig, Michael P.
    DiPersio, John F.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [40] Oxovanadium(IV) Cyclam and Bicyclam Complexes: Potential CXCR4 Receptor Antagonists
    Ross, Allison
    Soares, Dinesh C.
    Covelli, Danielle
    Pannecouque, Christophe
    Budd, Laura
    Collins, Anna
    Robertson, Neil
    Parsons, Simon
    De Clercq, Erik
    Kennepohl, Pierre
    Sadler, Peter J.
    INORGANIC CHEMISTRY, 2010, 49 (03) : 1122 - 1132